All articles tagged with #ptau217
A long-term study of cognitively healthy adults found that plasma pTau217 levels forecast early Alzheimer’s pathology and future cognitive decline, often rising years before amyloid PET scans become positive, suggesting blood tests could enable earlier risk detection and screening for prevention trials.
A Mass General Brigham-led study shows a blood test measuring pTau217 can predict Alzheimer's risk years before symptoms appear, potentially enabling earlier, less invasive screening than PET scans; while promising, more research is needed to validate across diverse populations and translate these findings into clinical practice.
A study of 317 cognitively healthy adults over about eight years shows that the blood biomarker pTau217 tracks brain amyloid and tau buildup and can predict future Alzheimer's pathology years before signs appear, potentially matching or prefiguring PET scans. While promising, researchers caution that more diverse data and validation are needed before clinical use, and not all biomarker-positive individuals progress to dementia.
UC San Diego researchers identify plasma phosphorylated tau 217 (p-tau217) as a blood biomarker that predicted future dementia risk decades before symptoms, especially in older women and APOE ε4 carriers; its predictive power varies with age and hormone therapy history, suggesting potential for earlier prevention and monitoring, though not yet ready for routine clinical use.
A study using the Women’s Health Initiative Memory Study found that higher levels of the blood protein phosphorylated tau 217 (p-tau217) correlate with a greater risk of developing dementia years later, potentially predicting risk up to 25 years before symptoms in 2,766 women aged 65–79. Those with higher p-tau217 had more than a threefold increased risk, with the highest levels linked to about sevenfold risk. The findings suggest a blood-based biomarker could enable earlier brain-health monitoring and prevention, but it’s not yet recommended for routine screening and requires further validation across diverse populations.